RxDoctor Payments Data

Marcy McAdoo, MD

Internal Medicine · Brookfield, WINPI 1164434023

Payments from drug & device makers

$1,642in general payments, 2019–2025

Across 54 payments — averaging $30.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$353
  • AstraZeneca$193
  • Novo Nordisk$178
  • Astellas Pharma US Inc$166
  • GSK$146
  • Pfizer$122
  • plus $484 from 11 others

What the payments were for

  • Food & beverage$1,642100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,642 in reported general payments places this provider in the 90th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$53,287
Medicare patients
238
Services billed
600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$92,585
TrulicityDulaglutide30$43,883
JanuviaSitagliptin Phosphate36$29,674
FarxigaDapagliflozin Propanediol33$26,584
JardianceEmpagliflozin24$26,343
MyrbetriqMirabegron31$24,769
OzempicSemaglutide16$23,306
XareltoRivaroxaban17$17,305
Colesevelam Hcl18$8,043
Xtampza ErOxycodone Myristate11$6,213
Omeprazole168$3,744
Lisdexamfetamine Dimesylate14$3,564
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen109$3,546
Levothyroxine Sodium344$3,284
Atorvastatin Calcium368$3,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$122$92,585103 claims
AstraZenecaFarxiga$193$26,58433 claims
Boehringer IngelheimJardiance$59$26,34324 claims
Astellas Pharma US IncMyrbetriq$166$24,76931 claims
Novo NordiskOzempic$178$23,30616 claims
AbbVieSynthroid$11$2,92338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Brookfield

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →